An unmet need that will persist despite these positive results is to identify, during neoadjuvant therapy, which patients would need treatment with platinum compounds and which patients may be safely spared from their toxicities, since carboplatin is still widely used in the treatment of patients with HER2 overexpressing tumours. Here, ERBB2 is linked to neoplasm.